| |
FDA: Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients
|
| |
| |
On July 8, 2009, FDA granted approval to Isentress (raltegravir), for the treatment of HIV-1 infection in treatment-naïve patients. The recommended dose for treatment-naïve adult patients is Isentress 400 mg twice daily, with or without food.
The use of Isentress in treatment-naïve patients is based on a 48-week randomized, double-blind, active control trial to evaluate the safety and efficacy of Isentress 400 mg twice daily + emtricitabine + tenofovir versus Sustiva (efavirenz) 600 mg + emtricitabine + tenofovir. The proportion of patients with HIV RNA < 50 copies/mL was 87% for the Isentress group compared to 82% for the Sustiva group. The difference between Isentress and Sustiva with respect to HIV RNA < 50 copies/mL and the 95% confidence intervals is 4.7% (-1.3%, 10.6%).
Several other changes were made to the package insert and include the following major revisions -
Highlights Section:
DRUG INTERACTIONS heading was included along with a warning about use with UGT (UDP-glucuronosyltransferases) inducers other than rifampin, specifically, "Coadministration of ISENTRESS with drugs that are strong inducers of UGT1A1 may result in reduced plasma concentrations of raltegravir"
Full Prescribing Information Section:
Section 1: INDICATIONS AND USAGE was changed to incorporate use in treatment-naïve patients: "ISENTRESS is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. This indication is based on analyses of plasma HIV-1 RNA levels up through 48 weeks in three double-blind controlled studies of ISENTRESS. Two of these studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults and one was conducted in treatment-naïve adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response."
Section 5.2: WARNINGS AND PRECAUTIONS, Drug Interactions: this section removed because the information is sufficiently included in Section 7: DRUG INTERACTIONS
Section 6.1: Clinical Trials Experience, Treatment-Naïve Studies: This section now includes 48 week safety and laboratory data from Protocol 021.
Section 6.2: Postmarketing Experience: addition of paranoia and anxiety.
Section 7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents adds information for CYP1A2, CYP2B6 and methadone.
Section 12.4 Microbiology was updated to include the following headings and information:
Antiviral Activity in Cell Culture
- In addition, 5 clinical isolates of HIV-1 subtype B had EC95 values ranging from 9 to 19 nM in cultures of mitogen-activated human peripheral blood mononuclear cells.
Resistance
Treatment-Naïve Subjects: By Week 48 in the STARTMRK trial, the primary raltegravir resistance-associated substitutions were observed in 3 (1 with Y143R and 2 with Q148H/R) of the 6 virologic failure subjects with evaluable paired genotypic data.
Section 14 CLINICAL STUDIES includes 48 week efficacy data from Protocol 02.
Minor editorial changes were made to the patient package insert for consistency with other antiretrovirals.
The revised label will be available soon on the FDA web site at Drugs@FDA or through the National Library of Medicine's DailyMedsite.
Issentress (raltegravir) is an integrase inhibitor made by Merck & Co.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
|
|
| |
| |
|
|
|
